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Abstract: The management of chondral defects represents a big challenge because of the limited
self-healing capacity of cartilage. Many approaches in this field obtained partial satisfactory results.
Cartilage tissue engineering, combining innovative scaffolds and stem cells from different sources,
emerges as a promising strategy for cartilage regeneration. The aim of this study was to evaluate
the capability of a cell-free collagen I-based scaffold to promote cartilaginous repair after orthotopic
implantation in vivo. Articular cartilage lesions (ACL) were created at the femoropatellar groove
in rat knees and cell free collagen I-based scaffolds (S) were then implanted into right knee defect
for the ACL-S group. No scaffold was implanted for the ACL group. At 4-, 8- and 16-weeks
post-transplantation, degrees of cartilage repair were evaluated by morphological, histochemical and
gene expression analyses. Histological analysis shows the formation of fibrous tissue, at 4-weeks
replaced by a tissue resembling the calcified one at 16-weeks in the ACL group. In the ACL-S
group, progressive replacement of the scaffold with the newly formed cartilage-like tissue is shown,
as confirmed by Alcian Blue staining. Immunohistochemical and quantitative real-time PCR (qRT-PCR)
analyses display the expression of typical cartilage markers, such as collagen type I and II (ColI and
ColII), Aggrecan and Sox9. The results of this study display that the collagen I-based scaffold is highly
biocompatible and able to recruit host cells from the surrounding joint tissues to promote cartilaginous
repair of articular defects, suggesting its use as a potential approach for cartilage tissue regeneration.
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1. Introduction
The repair and healing capacity of articular cartilage after injury is complicated due to its avascular,
hypo-cellular and aneural nature [1]. For this reason, even a minor lesion may lead to progressive
damage and cartilage degeneration, determining osteoarthritis (OA) development. OA is a common
progressively degenerative disease involving primarily articular cartilage and further all joint tissues
and leading to severe pain and joint disability [2,3]. Several therapeutic approaches have been
developed for the treatment of articular cartilage defects, including autografts and osteochondral
allografts, microfracture, autologous chondrocyte and mesenchymal stem cell-based therapies [4,5].
However, the results reported in this field showed limited satisfactory results and the management
of chondral defects remains a big challenge. This is mostly due to the biochemical and mechanical
properties of the obtained engineered cartilage, which often do not match those of the native tissue [6].
Tissue engineering for regenerative approaches emerges as one of the most promising biomedical
applications for cartilage tissue regeneration. The latter is based on the use of innovative
biomaterials, which act as scaffolds, mimicking a three-dimensional (3D) extracellular matrix (ECM)
microenvironment, with or without the use of chondrocytes or mesenchymal stem cells from different
sources [7–10]. Over the past decades, several advances in this field have arisen, based on the innovative
techniques used for biomaterial characterization, design and functionalization [11,12].
The biomaterials used in cartilage engineering approaches should provide mechanical support,
shape, and cell-scale architecture for neo-tissue formation as cells expand and organize. In addition
to defining the 3D architecture for the neo-tissue, the scaffold provides the microenvironment
(synthetic temporary ECM) for regenerative cell recruitment, support, proliferation, differentiation
and, finally, neo-tissue formation [13]. The most commonly used degradable biomaterials nowadays
include some synthetic polyesters such as poly(l-glycolic acid) (PLGA) and poly(l-lactic acid) (PLLA)
and natural biopolymers such as collagen, alginate, fibrin and chitosan [14,15]. The natural polymers
show better biological properties that are more suitable for the native cartilage microenvironment,
promoting required biocompatibility, cellular responses and biodegradability [16]. Among them,
collagen type I is widely used for scaffold construction and cartilage tissue engineering approaches,
due to its high biocompatibility and widespread clinical usage [17–20]. Although there are many
scaffolds based on collagen, its long-term performance still shows an inferior mechanical property
and limited chondrogenic capacity. For this reason, improvements of the physical and structural
properties of collagen I-based scaffolds are still required, as stated and highlighted by Irawan et al.,
in the recently published review [21]. Recently, the biocompatibility and the chondrogenic potential
of a new 3D collagen type I-based scaffold has been evaluated by our research group both in vitro
and in vivo (etherotopic implantation) [22,23]. Our in vitro results performed using this scaffold in
combination with human adipose-tissue derived mesenchymal stem cells (hADMSCs) showed that the
scaffold is able to promote the early stages of chondrogenic cell differentiation and that the addiction
of specific inductive factors induces complete differentiation as highlighted both by specific cartilage
markers expression and typical chondrocyte morphology [22]. The most important cartilage markers
are represented by glycosaminoglycans (GAGs), collagen type II and aggrecan, which are typical
ECM components of hyaline cartilage that characterise the articular cartilage of diarthrodial joints.
Collagen type I, instead represents the main constituent of the fibrocartilage matrix, which possesses
completely different mechanical properties compared to hyaline cartilage [1,6]. Another important
chondrogenic marker is represented by SOX9, a transcription factor expressed by chondrocytes,
which are the only cell type present within the cartilage tissue. It has been identified as a regulator
of the chondrocyte lineage, essential for chondrocyte differentiation and cartilage formation. It is
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associated with the enhancement of collagen II and aggrecan synthesis within the cartilage matrix [24].
In vivo data obtained by subcutaneous implantation (heterotopic model) of a cell free scaffold showed
that it is biocompatible and able to recruit host cells and to guide them towards the chondrogenic
differentiation [22]. Furthermore, the cartilage-like microstructural properties of this biomaterial,
in terms of density and elasticity, were combined in a simple production process [25], which makes
this scaffold even very interesting to be evaluated for cartilage regenerative approaches. For this
reason, to further evaluate and emphasize the data obtained in our previous studies, the aim of the
present work was to continue the validation of this cell-free collagen I-based scaffold in an articular
cartilage lesion (ACL) orthotopic model in terms of host cells recruitment, ECM deposition and
cartilaginous repair promotion. The results of the present study complete the multi-step evaluation
process of the 3D collagen I-based scaffold and may pave the way to the use of the latter in the cartilage
regeneration approaches.
2. Results
2.1. 3D Scaffold Characterization before Implantation
The microstructural and morphological properties of the 3D ColI-based scaffold were evaluated
by SEM analysis as previously indicated [22,23]. Briefly, Figure 1 shows SEM images of the 3D
scaffold at different magnifications, displaying a high porosity of the scaffold with 3D intersected
pores without any defined alignment of the collagen fibers. Pore distribution analysis indicated a
frequency ( > 65%) of pores between 40 and 100 µm in size. The swelling test was performed to assess
the change of material structure clearly demonstrating that the collagen I-based scaffold is highly
hydrophilic and reaches a steady-state in less than 1 min. The volume of absorbed PBS was quantified
to evaluate the capability of the collagen scaffold to maintain the liquid assigned to the support of the
3D structure. After swelling, both diameter (6 ± 1%) and thickness (27 ± 9%) of the scaffold appeared
significantly increased.
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Figure 1. Scanning Electron Microscopy (SEM) images of the collagen-based scaffold. At higher 
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2.2. Morphological Evaluation of Explanted Femurs 
To assess the capability of the collagen I-based scaffold to promote cartilage restoration we 
performed macroscopic (Figure 2A) and microscopic (Figure 2B) evaluation on the explanted femurs 
at 4-, 8-, and 16-weeks post-surgery and orthotopic implantation. The hematoxylin and eosin (H&E) 
staining was used to study the microscopic morphology of the femoral articular cartilage in both 
groups (femurs with implanted collagen I-scaffolds: ACL-S group, and femurs without scaffolds: 
ACL group) in order to detect alterations. In the control group, articular cartilage showed a normal 
cytoarchitecture. In the superficial zone, cells appeared flat and small; in the middle and deep zone, 
chondrocytes were organised in columns; the tidemark was very strong and evident (Figure 2Ba). In 
the articular cartilage of the ACL group, the general tissue organization was completely altered due 
to the defect induction. The superficial, middle and deep zones, as well as the tidemark, were not 
observable anymore at all the time points (Figure 2Bb–d). At 4 weeks post-surgery, the H&E staining 
i r . Scanning Electron icroscopy ( ) i s f t c ll - s sc ff l . t i r
ifi ti , i t rc nected collagen fibres are det ctable within the scaffold. Scale bars: 100 µm in (a);
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2.2. orphological Evaluation of Explanted Femurs
To assess the capability of the collagen I-based scaffold to promote cartilage restoration we
performed macroscopic (Figure 2A) and microscopic (Figure 2B) evaluation on the explanted femurs
at 4-, 8-, and 16-weeks post-surgery and orthotopic implantation. The hematoxylin and eosin (H&E)
staining was used to study the microscopic morphology of the femoral articular cartilage in both
groups (femurs with implanted collagen I-scaffolds: ACL-S group, and femurs without scaffolds:
ACL group) in order to detect alterations. In the control group, articular cartilage showed a nor al
cytoarchitecture. In the superficial zone, cells appeared flat and s all; in the iddle and deep zone,
chondrocytes were organised in columns; the tidemark was very strong and evident (Figure 2Ba).
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In the articular cartilage of the ACL group, the general tissue organization was completely altered
due to the defect induction. The superficial, middle and deep zones, as well as the tidemark, were
not observable anymore at all the time points (Figure 2Bb–d). At 4 weeks post-surgery, the H&E
staining revealed a newly formed fibrous tissue (scar tissue) in the superficial zone at the surface of
the subchondral bone, corresponding to the defect repair (Figure 2Bb). At 8- and 16-weeks the scar
tissue tended to be progressively replaced by a tissue that appeared to be calcified, suggested by the
morphological aspect of the tissue and poor proteoglycans deposit, further evidenced by Alcian Blue
staining (Figure 3). The peri-native cartilage features appeared totally altered (Figure 2Bc,d). In the
articular cartilage of the implanted group (ACL-S), at 4-weeks post-surgery, the H&E staining showed
the presence of newly formed tissue at the interface between the subchondral bone and collagen
scaffold, which presented morphological features resembling a prechondrogenic mesenchymal-like
tissue, characterised by the spindle-shaped cells growing without any apparent internal organisation
(Figure 2Be). However, this observation has not been validated by specific stainings and would need to
be confirmed. Afterwards, the samples revealed the capacity of the biomaterial to recruit host cells that
infiltrated, adhered and grown within the scaffold (8-weeks, Figure 2Bf). A progressive integration
and replacement of the degradable collagen scaffold with the reparative newly formed cartilage-like
tissue were shown (16-weeks, Figure 2Bg).
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Figure 2. Cartilage repair evaluation through macroscopic and microscopic evaluation. (A) Macroscopic
evaluation of repair capacity of femoral articular cartilage explants after defect creation indicated with
black circles (ACL group) and in vivo scaffold implantation indicated with red circles (ACL-S group)
at 4-, 8- and 16-weeks; (B) Histological evaluation by H&E staining of femoral articular cartilage
samples after defect creation (ACL group) and in vivo scaffold implantation (ACL-S group) at 4-, 8- and
16-weeks: (a) control sample presenting a normal cartilage cytoarchitecture; (b) ACL group sample
at 4-weeks presenting fibrocartilage formation at the defect area level; (c,d) ACL group sample at
8- and 16-weeks presenting cartilage calcification corresponding to the defect area level; (e) ACL-S
group sa ple at 4- eeks presenting a prechondrogenic mesenchyme-like tissue features at the interface
between scaffold and the peri-native tissue; (f) ACL-S group sample at 8-weeks presenting matrix
deposition within the scaffold, suggesting host cell recruitment and their chondrogenic differentiation;
(g) ACL-S group sample at 16-weeks presenting a total scaffold reabsorption and replacement ith a
newly formed cartilage-like tissue. Scale bar: 100 µm. The inserts represent the image magnifications
(scale bar: 50 µm) to evidence the morphology changes observed in a time-dependent manner.
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Figure 3. Histochemical evaluation of the deposition of sGAGs in femoral articular cartilage samples at
4-, 8- and 16-weeks post-surgery revealed by the intensity of Alcian Blue staining through computerised
densitometric measurements and image analysis. (A) The inserts represent the image magnifications
(scale bar: 100 µm) analysed by the software: the red colour corresponds to high intensity Alcian Blue
staining. (a) control sample of articular cartilage; (b–d) ACL group samples at 4-, 8- and 16-weeks;
(e–g) ACL-S group samples at 4-, 8- and 16-weeks. Scale bars: 100 µm. (B) Graph representing staining
level expressed as densitometric count (pixel2) normalized to the area of each section expressed in
pixel2. Results are presented as the mean ± SD. Two-way ANOVA test followed by Tukey’s multiple
comparison test reported that all pairwise comparisons were significantly different (p-value < 0.0001)
except for ACL 8-weeks vs. ACL 16-weeks, which was not significant (ns.).
The evaluation of cartilage repair was also assessed by the deposition of sulfated
glycosaminoglycans (sGAGs) revealed by the intensity of Alcian Blue staining (Figure 3). In the ACL
group at 4-weeks, the newly formed fibrous tissue showed a low-intensity blue staining (Figure 3Ab),
which diminished progressively and in a significant way with the supposed calcification of the cartilage
tissue through the time points and, especially, at 16-weeks (p-value < 0.0001, Figure 3Ad,B). In the
ACL-S group (Figure 3Ae–g), the Alcian Blue staining was much stronger than in the defect control
group (ACL group). The internal repair integrity was underlined by the higher ECM deposition within
the scaffolds due to the recruitment of host cells, moreover, it appeared progressive through the time
points, especially at 16-weeks post-implantation (p-value < 0.0001, Figure 3Af,B).
2.3. Ex Vivo Evaluation of Cartilage Regeneration
Immunohistochemical staining with statistical analysis was carried out in all groups to evaluate
cartilage repair through the expression level of SOX9 (Figure 4A), a pivotal transcription factor for
cartilage formation and ECM cartilaginous structural molecules, Aggrecan (Figure 4A’), Collagen type
I (Figure 5A), and Collagen type II (Figure 5A’).
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Figure 4. Sox9 and aggrecan evaluation in femoral articular cartilage samples at 4-, 8- and 16-weeks
post-surgery. (A–A’) Immunohistochemical analyses: (a) control sample of articular cartilage; (b–d) ACL
group samples at 4-, 8- and 16-weeks; (e–g) ACL-S group samples at 4-, 8- and 16-weeks. In the
inserts, the red colour corresponds to brown staining (immune complexes labelled with chromogen);
scale bars 50 µm. (B–B’) Graph representing staining level expressed as densitometric count (pixel2)
normalized to the area of each section expressed in µm2. (C–C’) Relative quantitation (RQ) of gene
expression showing the time-course of Sox9 and Aggrecan in ACL (L) and ACL-S (S) groups, after 4-, 8-,
and 16-weeks from surgery. TUBB4a has been used as endogenous controls. Results are presented as
the mean ± SD. Differences between groups were evaluated by using a two-way ANOVA followed
by Tukey’s multiple comparison post-hoc test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns,
not significant). * CTRL vs 4-, 8-, 16- wks_L and 4-, 8-, 16-wks_S; $ 4-wks_L vs 8-, 16-wks_L and 4-,
8-, 16-wks_S; ∂ 4-wks_S vs 8-, 16-wks_L and 8-, 16-wks_S; β 8-wks_L vs 16-wks_L and 8-, 16-wks_S;
+ 8-wks_S vs 16-wks_L and 16-wks_S; † 16-wks_L vs 16-wks_S.
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ACL-S (p-value < 0.0001, Figure 4Af,4B) groups, to increase again at 16-weeks especially in ACL-S 
group (p-value < 0.001, Figure 4Ag,4B). Overall, the SOX9 expression was significantly higher in ACL-
S group when compared to defect control group (ACL group), both at 8- (p-value < 0.05, Figure 
4Af,4B) and 16-weeks (p-value < 0.0001, Figure 4Ag,4B). 
The expression profile of aggrecan showed a progressive increase through the time points, with 
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Figure 5. Collagen type I and collagen type II evaluation in femoral articular cartilage samples at 4-,
8- and 16-weeks post-surgery. (A–A’) Immunohistochemical analyses: (a) control sample of articular
cartilage; (b–d) ACL group samples at 4-, 8- and 16-weeks; (e–g) ACL-S group samples at 4-, 8- and
16-weeks. In the inserts, the red colour corresponds to brown staining (immune complexes labelled
with chromogen); scale bars 50 µm. (B–B’) Graph representing staining level expressed as densitometric
count (pixel2) normalized to the area of each section expressed in µm2. (C–C’) Relative quantitation
(RQ) of gene expression showing the time-course of ColI and ColII in ACL (L) and ACL-S (S) groups,
after 4-, 8-, and 16-weeks from surgery. TUBB4a has been used as endogenous controls. Results are
presented as the mean ± SD. Differences between groups were evaluated by using a two-way ANOVA
followed by Tukey’s multiple comparison post-hoc test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001;
ns, not significant). (D) Table showing the ratio of collagen II/collagen I (ColII/ColI). * CTRL vs 4-,
8-, 16-wks_L and 4-, 8-, 16-wks_S; $ 4-wks_L vs 8-, 16-wks_L and 4-, 8-, 16-wks_S; ∂ 4-wks_S vs 8-,
16-wks_L and 8-, 16-wks_S; β 8-wks_L vs 16-wks_L and 8-, 16-wks_S; + 8-wks_S vs 16-wks_L and
16-wks_S; † 16-wks_L vs 16-wks_S.
A very strong expression of SOX9 was seen at 4-weeks post-surgery, especially in the ACL group
(Figure 4Ab). It decreased significantly at 8-weeks in both ACL (p-value < 0.0001, Figure 4Ac,B) and
ACL-S (p-value < 0.0001, Figure 4Af,B) groups, to increase again at 16-weeks especially in ACL-S group
(p-value < 0.001, Figure 4Ag,B). Overall, the SOX9 expression was significantly higher in ACL-S group
when compared to defect control group (ACL group), both at 8- (p-value < 0.05, Figure 4Af,B) and
16-weeks (p-value < 0.0001, Figure 4Ag,B).
The expression profile of aggrecan showed a progressive increase through the time points, with
the highest peak at 16-weeks in the ACL-S group (Figure 4A’g). Overall, aggrecan expression was
always higher in the ACL-S group when compared to the defect control group and it was significant at
8- (p-value < 0.05, Figure 4A’f,B’) and 16-weeks (p-value < 0.001, Figure 4A’g,B’).
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Collagen type I expression was strong at 4-weeks (Figure 5Ae) and 8-weeks (Figure 5Af), in
the ACL-S group, decreasing significantly at 16-weeks post-surgery (p-value < 0.0001, Figure 5Ag,B).
However, the collagen I expression resulted significantly higher in the ACL-S group when compared
to the defect control (ACL group) at all time points: 4-weeks (p-value < 0.0001, Figure 5Ae,B), 8-weeks
(p-value < 0.0001, Figure 5Af,B), 16-weeks (p-value < 0.001, Figure 5Ag,B).
A very strong expression of collagen type II was seen at 4-weeks post-surgery, especially in
the ACL-S group in which it was significantly higher when compared to the defect control group
(ACL group) (p-value < 0.0001, Figure 5A’e,B’) and it decreased progressively through the time points
(Figure 5A’f,g). The expression profile of collagen II demonstrated a significant difference between
the ACL and ACL-S groups at 4-weeks (p-value < 0.0001, Figure 5A’b,e,B’) but not at 8- and 16-weeks
(p-value < 0.05, Figure 5A’c,d,f,g,B’).
A qRT-PCR analysis was performed on total RNA isolated from explanted scaffolds to evaluate the
expression of specific genes correlated to cartilage phenotype. The expression profiles of cartilaginous
genes, including ColI, ColII, Aggrecan and Sox9 at 4-, 8-, and 16-weeks were compared to control mRNA
levels. Logarithmic RQ values are reported in Figures 4 and 5.
Sox9 displayed a characteristic peak of expression at 4-weeks both in the ACL (RQ = 7.563) and in
ACL-S groups (RQ = 5.432) that decreased progressively over time (ACL group: 8-weeks, RQ = 2.199
and 16-weeks RQ = 1.143; ACL-S group: 8-weeks RQ = 2.580, 16-weeks RQ = 2.528), even if the ACL-S
group maintained a higher expression of Sox9 when compared to the ACL group (Figure 4C).
Aggrecan exhibited a lower expression until the 8th week with a peak of expression at the 16th week
in both groups, although the ACL-S group (RQ = 18.687) displayed a more pronounced expression
than the ACL group (RQ = 7.433) (Figure 4C’).
ColI showed an increased expression during the fourth week in both groups, RQ = 1.965 in the
ACL group and RQ = 2.612 in the ACL-S group, that decreased down to 0.792 and 1.085 at 16-weeks,
respectively for the ACL and ACL-S groups (Figure 5C).
Finally, ColII showed a distinctive peak of expression at 4-weeks for ACL-S (RQ = 7.388) with a
subsequent decrease and reduced modulation (3.355 orders of magnitude) until week 16; in contrast,
the ACL group showed a higher ColII expression at 8-weeks (RQ = 4.905) that subsequently decreased
to 1.671 orders of magnitude at week 16 (Figure 5C’). Moreover, the gene expression profile data
showed a ratio of ColII/ColI for ACL-S/ACL groups of 2.48 fold at 4-weeks, 0.82 at 8-weeks and 3.07 at
16-weeks post-surgery (Figure 5D).
3. Discussion
The aim of the present study was to evaluate the extent to which the cell-free collagen I-based
3D scaffold might support hyaline cartilage repair of femoral articular cartilage defects, created to
reproduce the ACL model, at 16-weeks post-surgery. The concept of using cell-free scaffolds in tissue
engineering is widely accepted and has been advanced by Omori et al., in 2008, in an interesting study
on laryngeal cartilage reconstruction in a canine model [26], where the authors suggested the successful
cartilage reconstruction by the in situ tissue engineering approach.
In the present study, the collagen I-based scaffolds were confirmed to be biocompatible, as already
demonstrated in our previous study [23] and as evidenced by the histological analysis of the
present study, showing total biodegradation and replacement of the biomaterial with the newly
formed cartilage-like tissue at 16-weeks post-implantation (Figure 2B). Moreover, as previously
revealed [22,27,28], the scaffolds showed good immune tolerance by the animals, as suggested by the
absence of scar-like tissue formation and inflammatory cell infiltration at the interface between the
scaffold and peri-native cartilage tissue (Figure 2B). Furthermore, the H&E and Alcian Blue staining
demonstrated that the collagen-based scaffold allowed the formation of an articular cartilage-like
tissue corresponding to the defect area at the femoropatellar groove level. It was underlined by the
significantly higher deposition of sGAGs at 16-weeks post-implantation (Figure 3g) when compared
to the defect control group (Figure 3d). The latter showed, instead, newly formed tissue resembling
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calcified tissue in the area corresponding to the defect, at the same time point. These data were
confirmed by immunohistochemical analysis, which showed a higher expression of cartilage markers
in ACL-S group samples, when compared to the ACL group samples (Figures 4 and 5), at all the time
points. The only exception regards the SOX9 expression, which at its highest peak, corresponded to the
ACL group sample at 4-weeks post-surgery (Figure 4Ab). The latter was probably due to the fact that,
at 4-weeks, we expected that the formation of fibrous tissue might be preceded by mesenchymal tissue
formation, characterized by a high SOX9 expression [29,30]. Afterwards, along with the probably
observed calcification-unlike process (8- and 16-weeks post-surgery) in the ACL group, a significant
decrease of SOX9 expression was observed (Figure 4Ac,d,B). It probably happened because the recruited
host cells were not supported by any 3D structure, like that given by the collagen I-based scaffold
(ACL-S group, Figure 4Ae–g). Indeed, it has been widely shown that the 3D architectural support
enhances and improves the cartilaginous matrix formation and stability [31–33]. SOX9 is a transcription
factor that plays a key role in chondrogenesis, both by driving the collagen type II and aggrecan
expression and by supporting the survival of chondrocyte [29,34]. Apart from the exception of week
4, the results of immunohistochemistry demonstrated that SOX9 expression was maintained always
higher in the ACL-S group, especially at 16-weeks post-implantation. These results were observed
also in the expression profiles of collagen II (Figure 5) and, especially, of aggrecan, which the highest
peak corresponded to the the ACL-S group at 16-weeks (Figure 4A’g). Another important observation
regards the expression profiles of collagen type I and II, which the highest peaks corresponded to the
ACL-S group at week 4, as seen in Figure 5Ae,A’e. This was probably due to the fact that at this time
point, the collagen I-based scaffolds still conserved their integrity, and have not yet undergone the
biodegradation process, which was observable at 8- and, even more, at 16-weeks after implantation
(Figures 2 and 3). However, the scaffold has not been specifically labelled and this observation would
need to be further confirmed. The collagen II high expression was also justified by the infiltrated cells
within the scaffolds, already synthesising this cartilage marker, and occupying a bigger area when
compared to the cartilage repair tissue at 8- and 16-weeks (Figure 2). The immunohistochemistry results
were further confirmed by the gene expression analysis, which presented the same expression profiles
of all the chondrogenic markers, as seen in Figures 4C and 5C. Overall, the results of histological,
histochemical, immunohistochemical and gene expression analysis confirmed that implantation of
collagen I-based scaffold within the cartilage defects of rats, improved the cartilage tissue regeneration
when compared to the group without the scaffolds.
4. Materials and Methods
4.1. Scaffold Features
Collagen I-based scaffolds used in the present study were manufactured by Fin-Ceramica Faenza
SpA (Faenza, Italy). The characterization and process of manufacturing were already widely defined
in our previous study [22] and summarised below. These supports present a cylindrical form
(8 mm diameter and 5 mm height) and are made up of equine type I collagen gel (1wt%) furnished in
aqueous acetic buffer solution (pH = 3.5) (Opocrin SpA, Modena, Italy). The development process
and physical and chemical features have been explained previously [22,23]. In Brief, collagen gel
was diluted in water and supplied by 0.1 M NaOH solution, up to the isoelectric point (pH = 5.5),
in which it precipitated in fibres. Subsequently, it was crosslinked at 37 ◦C by 48 h long immersion of
the fibres in NaHCO3/Na2CO3 (Sigma Aldrich, Milan, Italy) and Merck Millipore, aqueous solution
with a 1,4-butanediol-diglycidyl-ether (BDDGE) and freeze-dried for 25 h under vacuum conditions
(P = 0.29 mbar) to obtain a porous 3D structure. Finally, the collagen constructs were treated with
gamma-rays at a minimum of 25 kGy.
The characterisation of 3D collagen scaffolds from a morphological and microstructural point
of view was performed by scanning electron microscopy (SEM) by using an SEM-LEO 438 VP
(Carl Zeiss AG, Oberkochen, Germany). Before the analysis, 3D scaffolds were sputter-coated with
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gold. SEM images were assessed by image J software by calculating the mean pore diameter
(mean value of 67 ± 31 microns on a total of 327 pores) (Figure 1). The swelling ability of the material
was estimated on 20 cartilaginous cylindrical constructs (ø = 10 mm, h = 4 mm) and determined by
evaluating the weight increase and the percent increase in both dimensions [35], as already reported in
our previous study [22]. The data analysis did not include the outlier values (Huber test). The porosity
and density of collagen constructs were assessed with a glass pycnometer full of highly purified water
on n. 20 scaffolds (d = 18 mm; h = 4 30mm) [36]. Pore diameter was then calculated using the geometric
volume of the scaffolds and the mean value of the achieved densities [22].
4.2. Breeding and Housing of Animals, Experimental Design and Surgery Procedure
Twenty-seven 2-month-old healthy female Wistar outbred rats (Charles River Laboratories, Milan,
Italy), with a bodyweight of 300 ± 20 g, were used in the present study. The animals were kept in
polycarbonate cages (10.25”W × 18.75”D × 8”H) at controlled humidity and temperature (20–23 ◦C)
throughout the whole period of the experiment, with free access to food and water and a 12 h light/dark
photoperiod. The 27 animals were divided into three groups at three different time points as shown in
Table 1. The ACL groups consisted of rats submitted to surgical treatment to create defects inducing
the ACL model. In the CTRL group, only 4-week samples were taken into account for the analysis.
Table 1. Experimental groups.
Study Groups Time Points Number of Rats
CTRL 4, 8, 16 weeks n. 9 (3 × each time point)
ACL (only lesion) 4, 8, 16 weeks n. 9 (3 × each time point)
ACL-S (lesion + scaffold) 4, 8, 16 weeks n. 9 (3 × each time point)
Total anaesthesia (30 mg/kg Zoletil 100 + altadol 5 mg/kg + maintenance mixture of O2 and
isoflurane 2%–2.5%, Vibrac, Milan, Italy) was used for the surgery procedure. The electric clipper
was used to shave the right limb anterior portion, which was then cleaned with povidone iodine
(Sceptre Medical, New Delhi, India). The vertical incision was made through the medial border of the
skin around the knee cap and, subsequently, through the articular capsule. Afterwards, the patella was
moved laterally to expose the right limb femorotibial joint. By flexing the knee the femoral condyles
were exposed and a 1 mm × 1.5 mm sharp surgical forceps and needles were used to make a hole
within the articular cartilage at the level of the femoropatellar groove of the right limb. Each rat
from the ACL-S group received the same treatment, i.e., the collagen scaffolds were sterilely cut into
1 mm × 1.5 mm pieces and implanted into the femoral condyle hole on the right leg while no material
was implanted in rats from the ACL group. The implantation was made using press-fit fixation,
without supplementary fixation devices. The patella was then removed back, and the articular capsule
and skin were sutured by using a 3–0 polydioxanone suture (Figure 6). Post-surgery, one dose of
antibiotic Convenia® 0.1 mL/kg, (Vibrac, Milan, Italy), anti-inflammatory (Meloxicam 1 mg/kg) and
analgesic (Tramadol 5 mg/kg) drugs, was administered for 3 days. After surgery, the animals were free
to move in the cages without joint immobilization. During all the experimental period the suffering of
animals was monitored through their observation (weight, lameness, fur appearance, consumption of
food and water), performed once a day. The animals from all groups (CTRL, ACL and ACL-S) and all
the sub-groups (4-, 8- and 16-weeks) after the surgical procedures were sacrificed by carbon dioxide
(CO2) overdose. After euthanasia, femurs were explanted, cleaned of soft tissues and the samples were
processed for histological, immunohistochemical and gene expression analyses. All the procedures
were carried out at the Center for Advanced Preclinical In Vivo Research (CAPIR), University of
Catania, conformed to the guidelines of the Institutional Animal Care and Use Committee (I.A.C.U.C.)
of the University of Catania (Protocol n. 2112015-PR of the 14.01.2015, Italian Ministry of Health).
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The experiments were conducted in accordance with the Italian Animal Protection Law (116/1992) and
the European Community Council Directive (86/609/EEC).
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replacement and the articular capsule and skin suture. 
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Cartilage samples were washed in phosphate-buffered saline (PBS, Bio-Optica, Milano, Italy), 
fixed in 10% buffered-formalin (Bio-Optica, Milan, Italy) for 24 h at room temperature. Afterwards, 
the samples were dehydrated in graded ethanol (Bio-Optica, Milan, Italy), cleaned in xylene (Bio-
Optica, Milan, Italy) and paraffin-embedded (Bio-Optica, Milan, Italy), being careful to preserve the 
desired anatomical orientation. For the general evaluation of the morphological structure of the 
cartilage, the slides of 4–5 μm thickness were cut from the obtained paraffin blocks and haematoxylin 
and eosin-stained (H&E; Bio-Optica, Milan, Italy) as previously described [33]. The samples were 
then examined with a Zeiss Axioplan light microscope (Carl Zeiss, Oberkochen, Germany) and by a 
digital camera (AxioCam MRc5, Carl Zeiss), used to take images. 
For qualitative histological analysis the following parameters were analysed: 
• The type of repaired tissue on the lesion surface (cartilaginous, fibrous or calcified); 
• Capability of the collagen I-based scaffold to recruit host cells and promote cartilaginous matrix 
deposition; 
• The scaffold biocompatibility and reabsorption of the collagen I-based scaffold. 
  
Figure 6. The photographs representing the surgical procedure performed to create defects
(ACL induction) and to implant a collagen I-based scaffold. (A) total anaesthesia induction; (B) knee
joint preparati n for the incision; (C–E) vertical incision through the ski and articular capsule along
the medial border and lateral displacement of the patella; (F–H) hole f r ti t t e level of the
femoropatellar gro ve in both ACL and ACL-S groups; (I) collagen I-based scaffold preparation and
cutting; (J) collagen I-based scaffold implantation into the hole in the ACL-S group only; (K,L) patella
replacement and the articular capsule and skin suture.
4.3. Histology Analysis
Cartilage samples were washed in phosphate-buffered saline (PBS, Bio-Optica, Milano, Italy),
fixed in 10% buffered-formalin (Bio-Optica, Milan, Italy) for 24 h at room temperature. Afterwards,
the samples were dehydrated in graded ethanol (Bio-Optica, Milan, Italy), cleaned in xylene
(Bio-Optica, Milan, Italy) and paraffin-embedded (Bio-Optica, Milan, Italy), being careful to preserve
the desired anatomical orientation. For the general evaluation of the morphological structure of the
cartilage, the slides of 4–5 µm thickness were cut from the obtained paraffin blocks and haematoxylin
and eosin-stained (H&E; Bio-Optica, Milan, Italy) as previously described [33]. The samples were then
examined with a Zeiss Axioplan light microscope (Carl Zeiss, Oberkochen, Germany) and by a digital
camera (AxioCam MRc5, Carl Zeiss), used to take images.
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For qualitative histological analysis the following parameters were analysed:
• The type of repaired tissue on the lesion surface (cartilaginous, fibrous or calcified);
• Capability of the collagen I-based scaffold to recruit host cells and promote cartilaginous
matrix deposition;
• The scaffold biocompatibility and reabsorption of the collagen I-based scaffold.
4.4. Analysis of sGAGs by Histochemistry
The samples were obtained as described above. Alcian Blue staining (Bio-Optica, Milan, Italy)
was used to evaluate the expression of glycosaminoglycans (GAGs). The evaluation was made by
computerised densitometric measurements. The samples were observed with a Zeiss Axioplan light
microscope (Carl Zeiss, Oberkochen, Germany) and the images were taken using a digital camera
(AxioCam MRc5, Carl Zeiss, Oberkochen, Germany).
4.5. Immunohistochemistry (IHC) Analysis
Articular cartilage samples were processed for immunohistochemical analysis as previously
described [37]. In brief, the sections were de-waxed in xylene, hydrated in graded ethanol scale and
incubated in 0.3% H2O2/PBS to stop endogenous peroxidase activity for 30 min. Afterwards, the slides
were cleaned for 20 min with PBS (Bio-Optica, Milan, Italy). The slides were heated in a microwave
oven (5min×3, 750W, LG Electronics Italia S.p.A., Milan, Italy) in Tris-EDTA buffer (pH 8.0; Bio-Optica,
Milan, Italy) or in citrate buffer–pH 6 (pH 6.0; Bio-Optica, Milan, Italy), for the antigenic retrieval [38].
Afterwards, the slides were incubated overnight at 4 ◦C with diluted rabbit polyclonal antibodies
against types I collagen (ab34710; Abcam, Cambridge, UK) and type II collagen (ab34712; Abcam,
Cambridge, UK); rabbit monoclonal anti-SOX9 (ab185966; Abcam, Cambridge, UK) and anti-aggrecan
(ab3778; Abcam, Cambridge, UK) antibodies, diluted 1:100 in PBS (Sigma-Aldrich, Milan, Italy).
Immune-complexes were then incubated with biotinylated link antibodies (HRP-conjugated anti-rabbit
and anti-mouse were used as secondary antibodies) and detected with peroxidase-labelled streptavidin
(LSAB + System-HRP, K0690, Dako, Glostrup, Denmark). Immunoreactivity was labelled using
0.1% 3,3′-diaminobenzidine (DAB) (DAB substrate Chromogen System; Dako, Glostrup, Denmark).
The Mayer’s hematoxylin (Histolab Products AB, Göteborg, Sweden) was used for the counterstain
and then the sections were mounted in GVA (Zymed Laboratories, San Francisco, CA, USA), observed
with an Axioplan Zeiss light microscope (Carl Zeiss, Oberkochen, Germany) and captured with a
digital camera (AxioCam MRc5, Carl Zeiss, Oberkochen, Germany).
4.6. Computerized Morphometric Measurements and Image Analysis
One field of about 550,000 µm2, corresponding to the defect area, carefully selected from each
section (three sections for each time point), was analysed for histochemical assessment of Alcian
Blue staining, detecting GAGs expression, and to quantify the level of positive anti-Collagen I,
anti-Collagen II, anti-Aggrecan and anti-SOX9 antibodies immunoexpression. The image analysis
software (AxioVision Release 4.8.2-SP2 Software, Carl Zeiss Microscopy GmbH, Jena, Germany),
which quantifies the staining level as the densitometric count (pixel2) normalized to the defect
area of each sample, was used. The samples were analysed by using the Zeiss Axioplan light
microscope (Carl Zeiss, Oberkochen, Germany) and the pictures were taken with a digital camera
(AxioCam MRc5, Carl Zeiss, Oberkochen, Germany). Two investigators (one anatomical morphologist
and one histologist) made the morphological assessment. If disputes occurred, a unanimous agreement
was reached after section re-evaluation and before proceeding with data interpretation.
4.7. Quantitative Real-Time Polymerase Chain Reaction (q-PCR)
Total RNA was isolated from paraffin-embedded tissue sections by using the RNeasy FFPE
Kit (Qiagen, Germantown, MD, USA). cDNA was synthesised from 1 µg of total RNA using a
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High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was
performed using the SYBR Green method on a 7900HT Real Time PCR (Applied Biosystems).
Specific primers for chondral genes, including COL1A1, COL2A1, aggrecan and SOX9, were
designed using Primer Blast [39] and selecting exon-exon junctions on mRNA as a target region for
annealing. Gene expression was assessed using the 2−∆∆Ct method [40]. Oligonucleotide sequences
are reported in Table 2. Results were normalised to the levels of Beta-Tubulin (TUBB), used as an
endogenous control.
Table 2. Primer sequences.







The statistical evaluation was carried out by using GraphPad Instat® Biostatistics version 3.0
software (GraphPad Software, Inc., La Jolla, CA, USA), as previously described [41]. Differences
between experimental groups were evaluated by using a two-way ANOVA followed by Tukey’s multiple
comparison post hoc test. Datasets were tested for normal distribution with the Kolmogorov–Smirnov
test. All variables were normally distributed. For all experiments, p-values of less than 0.05 were
considered statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 and ns, not significant).
The data are presented as the mean value ± SD, as previously described [42].
5. Conclusions
In conclusion, our data support the high biocompatibility of the collagen I-based scaffold, which
is able to efficaciously integrate into the host articular cartilage and to promote the development
of new cartilage-like tissue by recruiting the host cells and driving them towards the chondrogenic
differentiation. Moreover, thanks to the good biodegradability over time (up to 16-weeks), this scaffold
represents a promising tool for cartilage tissue engineering and repair approaches.
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